Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
SCYX.US
id: 867

Scynexis (SCYX) Allergic Medicines Case

D. New Jersey
Court
2:23-cv-22082
Case number
31 Mar 2023
Class period Start
22 Sept 2023
Class period End
06 Jan 2024
Lead Plaintiff motion deadline
  • Scynexis recalled its medicines due to potential allergic reactions.
  • On September 26, 2023, the truth came out, leading to a 11% $SCYX fall.
On September 25, 2023, Scynexis recalled its antifungal medication ibrexafungerp and temporarily halted clinical trials due to contamination risk.

This was caused by an unwanted substance found during production that could lead to allergic reactions and hypersensitivity.

This news caused $SCYX fall by 11% and $9.29M loss of market cap, damaging shareholders.

Given all this information, investors have reason to suspect that Scynexis misled about the effectiveness and safety of its drug.
Case Status
Lead Plaintiff Appointed
Alleged Offence
Mismanagement
Misleading Statements
Negligence
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
26 September 2023
Filing date
07 November 2023
Lead Plaintiff Deadline
06 January 2024
Collecting participants…

Scynexis Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of ...

    Ticker
    SCYX.US
    ISIN
    US8112922005
    CIK
    1178253
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Country
    USA
    Address
    1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548